{
    "title": "111_s422",
    "content": "The Act is titled the \"Heart Disease Education, Analysis Research, and Treatment for Women Act\" or the \"HEART for Women Act.\" It focuses on reporting data in applications for drugs, biologics, and devices. The HEART for Women Act amends the Federal Food, Drug, and Cosmetic Act regarding new drug applications, specifically addressing clinical data requirements for application approval. The Secretary must modify application requirements to include clinical data on drug safety and effectiveness by gender, age, and racial subgroup. Approved applications will have information made public online, subject to certain laws. Guidance will be developed for FDA staff on these applications. The FDA will review applications to ensure they contain required information. The Secretary can place a clinical hold on investigations if requirements are not met. Reports must include specified data. The FDA will review applications to ensure they contain required information, and the Secretary can place a clinical hold on investigations if requirements are not met. Reports must include specified clinical data related to the safety and effectiveness of drugs by gender, age, and racial subgroup. Amendments are made to sections regarding Biologics License Applications and Devices in the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. Amendments are made to sections regarding Biologics License Applications and Devices in the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, including the addition of new requirements for clinical data submission for premarket approval of devices. The amendments made to the Federal Food, Drug, and Cosmetic Act include provisions for premarket approval of devices and investigational devices, aligning them with the regulations for drug approval. Rules of construction prevent misinterpretation of the Act and its amendments. The Act does not establish new requirements for clinical investigations under the Federal Food, Drug, and Cosmetic Act. It also does not affect the Secretary of Health and Human Services' authority to enforce regulations not explicitly mentioned in the Act. These provisions apply only to applications received after the Act's enactment date. SEC. 3. REPORTING AND ANALYSIS OF PATIENT SAFETY DATA. The Secretary will ensure that nonidentifiable patient safety data is stratified by sex. Section 923(c) of the Public Health Service Act is amended to include analyzing data related to women and disparities in treatment quality between males and females.\n\nSEC. 4. QUALITY OF CARE REPORTS BY THE AGENCY FOR HEALTHCARE RESEARCH AND QUALITY. Section 903 of the Public Health Service Act is amended to include reporting on the quality of and access to care for women with heart disease, stroke, and other cardiovascular diseases. The Secretary must submit an annual report to Congress with recommendations for improving treatment and eliminating disparities in women's cardiovascular health. SEC. 5. EDUCATIONAL CAMPAIGNS. The Secretary of Health and Human Services will distribute educational materials on heart disease, stroke, and cardiovascular diseases to females aged 65 or older, physicians, and healthcare professionals. An education and awareness campaign will be conducted for healthcare professionals on the prevention, diagnosis, and treatment of these diseases in women. The Bureau of Health Professions may carry out contracts with public and private nonprofit entities to address cardiovascular diseases in women. The Wisewoman Program under the Public Health Service Act is extended with increased funding authorized for fiscal years 2010 to 2014."
}